The obligation to provide antiretroviral treatment in HIV prevention trials
Providing antiretroviral therapy (ART) to participants who seroconvert during HIV prevention trials in developing countries is an ethical expectation. Promising treatment to the few seroconverters widens disparities within a resource-poor country and would be unjust. Such an assurance should be done in a way that also improves access to ART for others in the country. US funds for ART in poor countries from the PEPFAR should be available to all countries that host HIV prevention and clinical trials
Lo, B., Padian, N., & Barnes, M. (2007). The obligation to provide antiretroviral treatment in HIV prevention trials. AIDS, %19;21(10), 1229-1231.